Your Health Questions
Answered by Professionals

There are several factors to consider; see below for crucial details. Persistent symptoms despite IBS meds often mean the problem is Crohn’s, especially fistulizing disease that IBS drugs cannot heal, with red flags like rectal drainage, perianal infections, bleeding, weight loss, or nighttime diarrhea. Effective relief now centers on biologics as first line, sometimes with immunomodulators or antibiotics plus surgical help or newer options like stem cell therapy, alongside nutrition support and stopping smoking, and the details below can help you choose next steps and know when to seek urgent care.

If your IBS pain, bloating, constipation, or diarrhea persists, treatments often fail because they are mismatched to your subtype, target symptoms instead of triggers, and ignore gut brain factors, food sensitivities, and overlapping conditions. There are several factors to consider. Medically proven next steps include confirming the diagnosis and red flags, matching therapy to your IBS subtype, using a layered plan that combines gut brain therapies with targeted meds and strategic low FODMAP reintroduction, and assessing the microbiome and overlapping conditions. See below for the complete guidance that can impact which next steps you take.

Why is cetirizine hydrochloride not stopping my itch? Cetirizine often fails when the itch is not histamine-driven, the dose or timing is suboptimal, triggers are physical, or you have chronic urticaria. Medically approved next steps include: - Supervised dose increases (up to fourfold) or switching antihistamines - Adding an H2 blocker or leukotriene inhibitor - Short steroid courses or biologics like omalizumab - Targeted treatment for eczema or dermatitis - Reviewing other medications that may contribute Seek urgent care for breathing trouble, throat swelling, severe dizziness, or fainting. Because persistent itch can stem from many overlapping causes—and the right treatment depends on pinpointing the underlying trigger—it's worth getting a clearer picture before your next doctor's visit. Take a free, instant, online <a href="https://ubiehealth.com/symptom-checker">symptom check</a> to better understand what's driving your itch and confidently navigate your next steps. Reviewed for medical accuracy: 06/25/2026

There are several factors to consider. For treatment-resistant depression, ECT offers faster relief with higher response rates of about 70 to 90 percent and is preferred for severe or urgent cases, while TMS shows about 50 to 60 percent response, is outpatient without anesthesia, and avoids memory problems. Your best choice depends on severity, urgency, side effect preferences, and practical issues like time and insurance. See the detailed pros and cons, safety notes, maintenance options, and urgent warning signs below to guide your next steps with your clinician.

Persistent sadness despite therapy and medication can reflect the brain needing more time, a mismatched drug, treatment-resistant depression, unrecognized medical issues, trauma needing specialized care, or sleep and lifestyle factors. See below for key details that can change which next steps are right for you. Next steps include a medication review if there is no improvement after 6 to 8 weeks, basic labs for thyroid, B12, D, and iron, reassessing therapy fit or trying structured CBT or trauma-focused work, discussing advanced options like TMS or esketamine, optimizing sleep and alcohol use, and seeking urgent help for any suicidal thoughts.

Bipolar treatment is moving toward personalized, preventive care that uses precision psychiatry to guide medications, refined brain stimulation options, digital early warning systems, and targeted psychotherapy plus sleep and routine stabilization. There are several factors to consider, including suicide risk management, subtyping, and earlier detection, and while there is no single cure, sustained, coordinated care can improve stability. See below for specific protocols, emerging options like ketamine, anti inflammatory and metabolic approaches, and long acting injectables, along with next steps to discuss with your clinician.

There are several factors to consider if bipolar symptoms persist after appropriate treatment; see below to understand more. Treatment resistance typically means symptoms continue after at least two adequate medications, and next steps can include optimizing mood stabilizers like lithium, adding atypical antipsychotics, reassessing for coexisting or misdiagnosed conditions, and considering ECT, ketamine or esketamine, TMS, and structured psychotherapy while protecting sleep and other routines. For urgent warning signs like suicidal thoughts, severe agitation, or psychosis, seek immediate care, and see the detailed plan below to decide which options fit your situation.

If symptoms persist despite medication and therapy, a holistic evidence-based plan that adds sleep and social rhythm stabilization, nutrition, steady exercise, stress reduction, substance-use support, and medical screening can reinforce mood stability, reduce relapse risk, and improve quality of life while complementing, not replacing, psychiatric care. There are several factors to consider, including tracking early warning signs and knowing when to seek urgent help, which can shape your next steps. See complete details below.

New antipsychotics offer more targeted treatment when older drugs are not enough, using partial dopamine agonism and effects on multiple neurotransmitters, plus long acting injectables that improve adherence and may better address persistent positive, negative, and cognitive symptoms with fewer movement side effects. There are several factors to consider for next steps, including a medication review, adherence options like injectables, lab monitoring, adding therapy, addressing sleep and substances, and considering clozapine if treatment resistant; see below for expert details, urgent warning signs, and nuances that could change your plan.

Newest FDA approved treatments for depression in 2026 include rapid-acting NMDA-targeting options like esketamine and the oral dextromethorphan-bupropion combo, plus expanded device-based care such as TMS and updated VNS that offer faster relief and new brain targets for people who have not improved with prior antidepressants; tightly regulated psychedelic-inspired care is also emerging. There are several factors to consider, including eligibility, safety monitoring, access and cost, insurance coverage, and how to combine these with therapy for best results. See the complete details below to guide your next steps.

If you are still struggling despite traditional treatment, there are several factors to consider. Next generation bipolar drugs provide more targeted mechanisms, better coverage of bipolar depression, and often improved tolerability, spanning newer atypical antipsychotics, dopamine and serotonin stabilizers, glutamate-modulating options, and long-acting injectables. See below to understand more, including who should consider a switch, key side effects and monitoring, adherence supports, and how combining medication with therapy and structured routines can guide your next steps.

The FDA pipeline for bipolar disorder is active and bringing tangible breakthroughs, from rapid-acting options for bipolar depression that work via glutamate pathways to long-acting injectables that improve adherence, targeted treatments for mixed episodes, and newer agents with fewer metabolic side effects, plus novel approaches involving inflammation and circadian regulation, with recent approvals already expanding choices. There are several factors to consider when choosing next steps; see below for the complete details that could affect your care, including benefits and risks, urgent warning signs, and how to discuss newer therapies with your clinician or use a symptom check to prepare.

New long-term medical data shows vagus nerve stimulation can deliver growing benefits over 1 to 5 years for treatment-resistant depression, with higher response and remission rates than treatment-as-usual and a possible drop in suicide risk. There are several factors to consider, see below to understand more. It is not a quick fix and requires careful screening and awareness of side effects, and there are also non-implant options being studied, so review the details below to learn who may benefit and what steps to discuss with your clinician.

Refractory bipolar disorder means persistent manic, depressive, hypomanic, or mixed symptoms despite at least two adequate medication trials, often due to misdiagnosis, subtherapeutic dosing or interactions, sleep disruption, rapid cycling or mixed features, substance use, or medical issues like thyroid or vitamin deficiencies. Next clinical steps include optimizing mood stabilizers such as lithium and combination regimens, targeted options for bipolar depression, and advanced treatments like clozapine, ketamine or esketamine, ECT, and TMS, alongside circadian-focused care and evidence-based psychotherapy. There are several factors to consider, with specific labs, safety warnings, and decision pathways detailed below.

There are several reasons your brain can resist mood disorder management, including slow-to-shift brain chemistry, depressive thinking patterns, low energy, stress or trauma, and the need for treatment adjustments and consistency. There are several factors to consider; see below for practical next steps like reassessing your plan with a clinician, starting smaller, protecting sleep, reducing isolation, and knowing urgent warning signs that need immediate care, plus more details that could change which steps you take in your healthcare journey.

Circadian rhythm disruption is a leading, underrecognized cause of ongoing bipolar mood swings; aligning sleep timing, light exposure, and daily routines can lower relapse risk and improve stability. Evidence-based next steps include IPSRT, strict sleep protection with a fixed wake time, carefully supervised light therapy, evening blue-light reduction, medication timing review, and plans for travel and seasonal shifts, with clear guidance on when to seek urgent care. There are several factors to consider that can change your next steps; see below for key details and safety considerations.

Fecal transplant trials are a research based next step for IBS when diet changes, fiber, probiotics, medications, and stress management have not helped, targeting the gut microbiome; early studies show some people improve, often those with IBS-D, though results are mixed and participation within trials is safer than unregulated clinics. There are several factors to consider; see below to understand who might be a candidate, how trials are done and monitored, potential risks and red flag symptoms to rule out other diseases, and which standard treatments to try or optimize before enrolling.

Persistent IBS symptoms may reflect incomplete testing, gut brain miscommunication, microbiome imbalance, hidden food triggers, or subtle inflammation that suggests IBD rather than IBS. There are several factors to consider; see below to understand more and to learn which red flags require urgent care. New IBD specialist protocols use precise diagnostics and early, personalized treatment plans, including advanced medications, gut directed therapies, targeted probiotic and diet strategies, and structured follow up, and the complete details below can help you decide when to search for an IBD specialist near me and what to do next.

Still suffering with Crohn’s disease or ulcerative colitis despite treatment? Mayo Clinic’s IBD clinical trials provide research-backed access to emerging biologics, oral small molecules, microbiome approaches, and precision strategies with close specialist monitoring, though suitability depends on your diagnosis, disease activity, and prior medication response. There are several factors to consider. See below to understand more about eligibility, safety and placebo use, potential benefits and risks, urgent warning signs, and concrete next steps for discussing enrollment with your gastroenterologist.

New long-term data show that modern Crohn’s drugs are generally safe over years, with serious side effects uncommon; infections are a manageable risk with screening and vaccines, anti-TNFs carry a small lymphoma signal especially with thiopurines, and gut selective options like vedolizumab plus IL-12/23 and IL-23 agents have reassuring profiles while reducing hospitalizations, surgery, and steroid exposure. There are several factors to consider before choosing or adjusting therapy, including age, prior infections or cancer, pregnancy plans, and use of combination immunosuppression. See below for drug-by-drug risks, who needs extra caution, and when to call your doctor so you can decide your next steps confidently.

There are several factors to consider. Newer, more selective oral JAK inhibitors like upadacitinib, filgotinib, and the TYK2 agent deucravacitinib can provide strong symptom relief with potentially fewer side effects than earlier JAKs, but risks remain and depend on age, cardiovascular and clotting risks, infection risk, and cancer history. Next steps include confirming your diagnosis and disease activity, reviewing vaccines and baseline labs, and discussing with your rheumatologist whether a newer JAK inhibitor, a different biologic, or combination therapy fits your risk profile and goals; see the complete guidance below for key cautions, monitoring needs, and questions to ask that could change your plan.

IBD gene therapy is an emerging, research-stage approach that targets the root genetic and immune drivers of Crohn’s disease and ulcerative colitis to reduce inflammation more precisely than standard drugs, using methods like anti-inflammatory gene delivery, RNA-based silencing, and engineered microbiome therapies. It is not yet standard care, and benefits, risks, and eligibility differ by patient and trial, but it may offer longer-lasting relief for those not responding to current treatments. There are several factors to consider; see the complete details below to guide next steps with your gastroenterologist, from clinical trial options and genetic testing to red flags that need urgent care.

The latest FDA approved drugs for IBD in 2026 give people with Crohn’s disease and ulcerative colitis more precise options, including IL-23 inhibitors, next-generation JAK inhibitors, S1P modulators, and emerging dual-targeted approaches that can raise remission rates, cut steroid use, and add convenient oral choices. There are several factors to consider, so talk with your gastroenterologist about fit based on disease severity, prior drug response, safety risks, and practical issues like pregnancy or insurance, and see the complete details below for which option to ask about, how to prepare for your visit, and urgent symptoms that need immediate care.

If you’re still struggling with Crohn’s disease or ulcerative colitis, Mount Sinai IBD research recruitment may offer access to emerging therapies, close expert monitoring, and a chance to contribute to future care, with some study costs often covered. There are several factors to consider, including eligibility, risks such as side effects or placebo, and how participation fits with your current treatment, so talk with your gastroenterologist. See below for key details on who qualifies, what to expect, safety oversight, potential costs, and when to seek urgent care.

New IL-12/23 inhibitors in the pipeline may be a breakthrough for people still struggling with psoriasis, psoriatic arthritis, or IBD, offering more precise targeting, longer-lasting responses with fewer injections, and higher skin clearance even after prior biologic failure. There are several factors to consider, including how these compare with IL-23 only options and which patient profiles may benefit most. Safety and next steps matter, such as infection risks, TB screening, vaccination review, symptom tracking, and asking about clinical trials or switching therapies with your clinician. See the complete answer below for key details that could change your next steps.

Perianal Crohn’s trials offer regulated, medically guided next steps when standard treatments are not enough, giving access to advanced biologics and innovative options like stem cell approaches with expert oversight while helping drive future approvals. There are several factors to consider, including eligibility, safety safeguards, how a study may work with your current meds, and when to seek urgent care. See below for the complete details, key questions for your doctors, and practical next steps that can shape your care plan.

There are several factors to consider. Severe IBD treatments can fail for multiple reasons, including primary nonresponse, loss of response from low drug levels or antibodies, incorrect or overlapping diagnoses, structural complications that medication cannot reverse, and adherence or lifestyle triggers. Next clinical steps include objective testing and therapeutic drug monitoring, switching or combining therapies with a treat to target plan, advanced imaging, timely surgical consultation, and exploring clinical trials; see below for key nuances, red flag symptoms, and decision points that could change your next move.

There are several factors to consider: IBD is an autoimmune misfire that can keep inflaming the gut despite treatment, and 30 to 40 percent of people do not reach durable remission on first-line therapies due to loss of response, side effects, or aggressive disease; see below to understand more. Clinical trials can provide access to advanced options and close monitoring but carry real risks, including no benefit or placebo, disease worsening, unknown side effects, medication restrictions, and a heavy visit burden; see the complete guidance below on trial phase, rescue plans, cost coverage, alternatives, and warning signs that may require urgent care and a doctor discussion.

There are several factors to consider; see below to understand more. Persistent symptoms despite optimized mesalamine and steroids may reflect inadequate rectal drug reach, undertreatment or adherence issues, steroid dependence, disease extension, or infection, and next steps include objective reassessment plus escalation to advanced therapies such as biologics (anti-TNF, vedolizumab, ustekinumab), oral small molecules (JAK inhibitors, ozanimod), and consideration of investigational options or clinical trials.

There are several factors to consider if you are still symptomatic on infliximab; see below to understand more, including target trough ranges and urgent red flags. A common, fixable cause is low infliximab trough levels due to rapid clearance from active inflammation, anti-drug antibodies, or under-dosing, which therapeutic drug monitoring can confirm. Next steps often include increasing the dose, shortening infusion intervals, adding an immunomodulator, or switching therapies, while checking for noninflammatory causes if levels are adequate.